I would consider any entry a trade, and not an investment.
Any modest intraday dip is probably a buying opportunity.
Did you ever think that could be allowed? That our government let that happen? No one seemed to think about it until now. The answer, like the coronavirus, is we knew.
There are multiple reasons why these stocks often decline after their drugs receive the blessing of regulators.
Alexion Pharmaceuticals and Lantheus Holdings are interesting names at current trading levels.
Dynavax Technologies and Omeros Corp. have tested shareholders' patience over time and again are at inflection points.
I think, ultimately, the big issue for many will be what happens in the United States if we hear about people who didn't go to China who have come down with the disease.
Gilead offers a nearly 4% yield and looks ready to return to growth.
Stemline Therapeutics, Entercom Communications and Ocular Therapeutix offer reasons to think their shares will perform better in the New Year.
Let's review the charts of Allakos and Global Blood Therapeutics.